The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma: Epigenetic silencing, clinical features, and prognostic significance

Cancer

Volumn 106, Issue 10, 2006, Pages 2190-2199

  Sugio, Kenji ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Immunonistochemistry; Lung carcinoma; Methylation; Prognosis; Protein expression

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN P16INK4A; UVOMORULIN;

ADULT; AGED; ARTICLE; CDH1 GENE; CLINICAL FEATURE; CPG ISLAND; EPIGENETICS; FEMALE; FHIT GENE; GENE; GENE FREQUENCY; GENE INACTIVATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; P16 INK4A GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METHYLATION; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; BASE SEQUENCE; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SAMPLING STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646343483     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21870     Document Type: Article

References (51)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
2. Naruke T, Tsuchiya R, Kondo H, et al. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg. 2001;71:1759-1764.
3. Forgacs E, Zochbauer-Muller S, Olah E, et al. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res. 2001;7:6-13.
4. Campling BG, el-Deiry WS. Clinical implications of p53 mutations in lung cancer. Methods Mol Med. 2003;75:53-77.
5. Kohno T, Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis. 1999;20:1403-1410.
6. Herman JG, Melro A, Mao L, et al. Inactivation of the CDKN2/p16/MST1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525-4530.
7. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst. 2000;92:1303-1307.
8. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249-255.
9. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691-699.
10. Yanagawa N, Trauma G, Oizumi H, et al. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci. 2003;94:589-592.
11. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60:5954-5958.
12. Eunice CC, Shui YL, Kenneth WT, et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalveolar lavage. Clin Cancer Res. 2002;8:3741-3746.
13. Slack A, Bovenzi V, Bigey P, et al. Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med. 2002;4:381-319.
14. Zochbauer-Muller S, Fong KM, Maitra A, et al. 5′CpG island methylation of FHIT gene is correlated with loss of gene expression in lung and breast cancers. Cancer Res. 2001;61:3581-3585.
15. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature. 2004;431:211-217.
16. Sugio K, Ishida T, Yokoyama H, et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 1992;52:2903-2906.
17. Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 mutation are an independent unfavorable prognosis indicator in patients with non-small-cell lung cancer. Br J Cancer. 1997;75:1125-1130.
18. Mitsudomi T, Oyama T, Nakanishi R, et al. Loss of heterozygosity at 3p in non-small cell lung cancer and its prognostic implication. Clin Cancer Res. 1996;2:1185-1189.
19. Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and β-catenin in human non-small cell lung cancer and clinical significance. Clin Cancer Res. 2000;6:4786-4796.
20. Taga S, Osaki T, Ohgami A, et al. Prognostic impact of telomerase activity in non-small cell lung cancers. Ann Surg. 1999;230:715-720.
21. Uramoto H, Sugio K, Oyama T, et al. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res. 2004;10:6905-6910.
22. Hung J, Kishimoto Y, Sugio K, et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA. 1995;273:1908.
23. Ohta M, Inoue H, Cotticelli MG, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996;84:587-597.
24. Sevignani C, Calin GA, Cesari R, et al. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res. 2003;63:1183-1187.
25. Morton RA, Ewing CM, Nagafuchi A, et al. Reduction of E-cadherin level and deletion α-catenin genes in human prostate cancer cell. Cancer Res. 1993;53:3585-3590.
26. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826.
27. INK4 expression in nonsmall cell lung carcinoma. Cancer.<.I 1997;80:389-395.
28. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 1998;58:5032-5037.
29. Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet. 1994;7:536-540.
30. Tsuchiya T, Tamura G, Sato K, et al. Distinct methylation patterns in normal and cancerous gastric epithelia. Oncogene. 2000;19:3642-3646.
31. Waki T, Tamura G, Tsuchiya T, et al. Promoter methylation status of E-cadherin hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol. 2002;161:399-403.
32. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylation phenotype in colorectal cancer. Proc Natl Acad Sci USA. 1999;96:8681-8686.
33. INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001;61:3419-3424.
34. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, et al. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implication. Int J Oncol. 2004;24:349-355.
35. Yanagawa N, Trauma G, Oizumi H, et al. Frequent epigenetic silencing of p16 gene in non-small cell lung cancers of tobacco smoking. Jpn J Cancer Res. 2002;93:1107-1113.
36. Rom WN, Hay JG, Lee TC, et al. Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med. 2000;161:1355-1367.
37. INK4A in primary rat lung tumors. Mol Cell Biol. 1997;17:1366-1374.
38. Lee YW, Klein CB, Kargacin B, et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol Cell Biol. 1995;15:2547-2557.
39. Sozzi G, Sard L, De Gregorio L, et al. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 1997;57:2121-2123.
40. Kim JS, Kim H, Shim YH, et al. Aberrant methylation of FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis. 2004;25:2165-2171.
41. Huebner K, Croce CM. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer. 2003;88:1501-1506.
42. Zhou H, Calaf GM, Hei TK. Malignant transformation of human bronchial epithelial cell with the tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1(3-pyridyl)-1-butanone. Int J Cancer. 2003;97:1002-1009.
43. Saito T, Nishimura M, Yamasaki H, et al. Hypermethylation in promoter region of E-cadherin gene is associated with tumor differentiation and myometrial invasion in endometrial carcinoma. Cancer. 2003;97:1002-1009.
44. Graziano F, Arduini F, Ruzzo A, et al. Prognostic analysis of E-Cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res. 2004;10:2784-2789.
45. Sugio K, Kase S, Sakada T, et al. Micrometastasis in the bone marrow of patients with lung cancer associated with a reduced expression of E-cadherin and beta-catenin: risk assessment by immunohistochemistry. Surgery. 2002;131: S226-S231.
46. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168-174.
47. INK4A gene in pulmonary adenocarcinoma and anthracosis in background lung. Int J Cancer. 1999;84:609-613.
48. Hirohashi S. Inactivation of the E-cadherin-mediated Cell adhesion system in human cancers. Am J Pathol. 1998;153:333-339.
49. Ino Y, Gotoh M, Sakamoto M, et al. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promoters. Proc Natl Acad Sci USA. 2002;99:365-370.
50. Ohira T, Gemmill RG, Ferguson K, et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA. 2003;100:10429-10434.
51. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene. 2002;21:5496-5503.